Phibro Animal Health (PAHC) Expected to Announce Quarterly Earnings on Wednesday

Phibro Animal Health (NASDAQ:PAHC) is projected to issue its Q2 2026 results before the market opens on Wednesday, February 4th. Analysts expect Phibro Animal Health to post earnings of $0.69 per share and revenue of $355.6360 million for the quarter. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, February 5, 2026 at 9:00 AM ET.

Phibro Animal Health (NASDAQ:PAHC) last issued its earnings results on Wednesday, November 5th. The company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.15. The firm had revenue of $363.89 million during the quarter, compared to analyst estimates of $345.44 million. Phibro Animal Health had a net margin of 4.85% and a return on equity of 36.26%. On average, analysts expect Phibro Animal Health to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Phibro Animal Health Stock Performance

PAHC opened at $39.52 on Wednesday. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.35 and a current ratio of 3.09. The stock has a market capitalization of $1.60 billion, a price-to-earnings ratio of 23.81, a PEG ratio of 1.12 and a beta of 0.79. The company has a fifty day moving average of $39.97 and a 200 day moving average of $37.69. Phibro Animal Health has a fifty-two week low of $16.16 and a fifty-two week high of $46.42.

Phibro Animal Health Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, December 17th. Stockholders of record on Wednesday, November 26th were given a dividend of $0.12 per share. The ex-dividend date was Wednesday, November 26th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.2%. Phibro Animal Health’s dividend payout ratio (DPR) is presently 28.92%.

Insiders Place Their Bets

In other Phibro Animal Health news, CEO Jack Bendheim sold 1,235 shares of the company’s stock in a transaction that occurred on Friday, January 23rd. The stock was sold at an average price of $40.55, for a total transaction of $50,079.25. Following the sale, the chief executive officer directly owned 15,445 shares in the company, valued at $626,294.75. This represents a 7.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders sold 154,635 shares of company stock worth $6,702,107 over the last quarter. Insiders own 50.13% of the company’s stock.

Institutional Trading of Phibro Animal Health

Hedge funds and other institutional investors have recently bought and sold shares of the stock. iSAM Funds UK Ltd purchased a new position in Phibro Animal Health during the third quarter worth $61,000. Advisory Services Network LLC bought a new stake in shares of Phibro Animal Health in the 3rd quarter worth about $96,000. EverSource Wealth Advisors LLC boosted its stake in shares of Phibro Animal Health by 7,671.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock worth $69,000 after purchasing an additional 2,685 shares during the period. Tower Research Capital LLC TRC grew its holdings in Phibro Animal Health by 768.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,610 shares of the company’s stock valued at $118,000 after purchasing an additional 4,079 shares during the last quarter. Finally, Creative Planning purchased a new stake in Phibro Animal Health in the 3rd quarter worth about $217,000. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Weiss Ratings reiterated a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. JPMorgan Chase & Co. lifted their price objective on Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Finally, Zacks Research raised Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $31.40.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.